Guizhou Sanli Pharmaceutical Co., Ltd. logo

Guizhou Sanli Pharmaceutical Co., Ltd. (603439)

Market Closed
11 Aug, 06:57
SSE SSE
¥
12. 65
+0.93
+7.9352%
¥
5.16B Market Cap
- P/E Ratio
0.8% Div Yield
26.21M Volume
- Eps
¥ 11.72
Previous Close
Add Transaction
Day Range
11.3 12.89
Year Range
9.51 17.46
Want to track 603439 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

603439 closed today higher at ¥12.65, an increase of 7.9352% from yesterday's close, completing a monthly increase of 1.0383% or ¥0.13. Over the past 12 months, 603439 stock gained 7.9352%.
603439 pays dividends to its shareholders, with the most recent payment made on Jun 30, 2026. The next estimated payment will be in In 10 months on Jun 30, 2027 for a total of ¥0.06.
The last earnings report, released on May 16, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.

603439 Chart

People also search for

Shenzhen YHLO Biotech Co., Ltd.
¥ 9.45
-1.0471%
Shinva Medical Instrument Co., Ltd.
¥ 12.68
-1.2461%
Inventisbio Co., Ltd.
¥ 20.96
+2.5942%
Vcanbio Cell & Gene Engineering Co., Ltd.
¥ 19.89
-0.3008%
Ningbo Yunsheng (Group) Co., Ltd.
¥ 12.3
-1.9139%

Guizhou Sanli Pharmaceutical Co., Ltd. (603439) FAQ

What is the stock price today?

The current price is ¥12.65.

On which exchange is it traded?

Guizhou Sanli Pharmaceutical Co., Ltd. is listed on SSE.

What is its stock symbol?

The ticker symbol is 603439.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.8%.

What is its market cap?

As of today, the market cap is 5.16B.

Has Guizhou Sanli Pharmaceutical Co., Ltd. ever had a stock split?

No, there has never been a stock split.

Guizhou Sanli Pharmaceutical Co., Ltd. Profile

Biotechnology Industry
Healthcare Sector
Mr. Hai Zhang CEO
SSE Exchange
CNE1000040B4 ISIN
CN Country
2,282 Employees
30 Jun 2026 Last Dividend
- Last Split
- IPO Date

Overview

GuiZhou SanLi Pharmaceutical Co., LTD., founded in 1995, is a prominent player in the pharmaceutical industry based in Anshun, China. The company specializes in the research and development, production, and marketing of a wide array of pharmaceutical products. Over the years, SanLi Pharmaceutical has established itself as a key supplier of various types of medications targeting different ailments and health conditions, catering to the needs of diverse patient groups. Its commitment to innovation and quality has helped it to carve a niche in the competitive pharmaceutical landscape of China.

Products and Services

Pediatric Medication: SanLi Pharmaceutical offers a comprehensive range of medications specially formulated for infants and children. These medications cater to the unique needs of this age group, ensuring safety and efficacy in treatment.

Respiratory System Medication: The company produces medicines aimed at treating and managing conditions affecting the respiratory system. This encompasses drugs for common ailments like asthma, bronchitis, and other respiratory disorders, providing relief and promoting better breathing.

Cardiovascular Drugs: Addressing the global challenge of cardiovascular diseases, SanLi provides a variety of drugs to combat conditions like hypertension, heart failure, and arrhythmias. Their cardiovascular range is designed to improve heart health and patient outcomes.

Injury by Fall Medication: Specializing in post-trauma care, SanLi Pharmaceutical formulates medications to support recovery from injuries caused by falls. This includes pain relievers, anti-inflammatory drugs, and compounds to accelerate healing processes.

Rehabilitation Medicine: The company also extends its portfolio to include rehabilitation medicines, aimed at helping patients regain mobility and improve their quality of life following physical impairments or surgeries.

GI Medicine: Understanding the prevalence of gastrointestinal disorders, SanLi Pharmaceuticals offers a variety of medications targeting issues like acid reflux, ulcers, and irritable bowel syndrome (IBS), among others, to improve digestive health.

Ophthalmic Medicine: Having recognized the importance of eye health, the company provides treatments for various ophthalmic conditions, including infections, glaucoma, and dry eye, ensuring comprehensive care for visual health.

Contact Information

Address: Xiayun Industrial Park, Anshun, China, 561100
Phone: 86 851 3811 3395